Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Total Revenue of $44.52 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +17.6% in Total Revenue from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2016 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $9.64 million | Q2 2017: $8.67 million | Q3 2017: $11.20 million | Q3 2017: $11.20 million | Q4 2017: $11.65 million | Q1 2018: $8.59 million | Q1 2018: $8.59 million | Q2 2018: $10.16 million | Q2 2018: $10.16 million | Q3 2018: $8.49 million | Q3 2018: $8.49 million | Q4 2018: $13.50 million | Q1 2019: $8.73 million | Q1 2019: $8.73 million | Q2 2019: $9.42 million | Q2 2019: $9.42 million | Q3 2019: $6.94 million | Q3 2019: $6.94 million | Q4 2019: $9.31 million | Q1 2020: $8.33 million | Q1 2020: $8.33 million | Q2 2020: $9.60 million | Q2 2020: $9.60 million | Q3 2020: $9.25 million | Q3 2020: $9.25 million | Q4 2020: $10.26 million | Q1 2021: $10.54 million | Q1 2021: $10.54 million | Q2 2021: $9.06 million | Q2 2021: $9.06 million | Q3 2021: $8.07 million | Q3 2021: $8.07 million | Q4 2021: $8.32 million | Q1 2022: $11.18 million | Q1 2022: $11.18 million | Q2 2022: $10.30 million | Q2 2022: $10.30 million | Q3 2022: $11.41 million | Q3 2022: $11.41 million | Q4 2022: $9.12 million | Q4 2022: $9.12 million | Q1 2023: $9.22 million | Q2 2023: $10.89 million | Q3 2023: $10.09 million | Q4 2023: $9.35 million | Q1 2024: $8.50 million | Q2 2024: $9.85 million | Q3 2024: $9.09 million | Q4 2024: $10.44 million | Q1 2025: $11.71 million | Q2 2025: $10.84 million | Q3 2025: $8.29 million | Q4 2025: $13.68 million.
- Over the full 11 years of available data (2016 to 2025), CUMBERLAND PHARMACEUTICALS INC's Total Revenue has grown by 34.8%.
- Historical annual values: Fiscal year 2025: $44.52 million | Fiscal year 2024: $37.87 million | Fiscal year 2023: $39.55 million | Fiscal year 2022: $42.01 million | Fiscal year 2022: $42.01 million | Fiscal year 2021: $35.99 million | Fiscal year 2020: $37.44 million | Fiscal year 2019: $34.39 million | Fiscal year 2018: $29.34 million | Fiscal year 2017: $41.15 million | Fiscal year 2016: $33.03 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: